Go Pro
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel Free CRSP Stock Alerts

CRISPR Therapeutics (CRSP) Financials

CRISPR Therapeutics logo
$53.90 -0.09 (-0.16%)
As of 02:01 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for CRISPR Therapeutics

Annual Income Statements for CRISPR Therapeutics

This table shows CRISPR Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -26 -23 -68 -165 67 -349 373 -650 -154 -366 -579
Consolidated Net Income / (Loss)		 -26 -23 -68 -165 67 -349 378 -650 -154 -366 -582
Net Income / (Loss) Continuing Operations		 -26 -23 -68 -165 67 -349 378 -650 -154 -366 -582
Total Pre-Tax Income 		-26 -23 -67 -164 67 -348 380 -651 -151 -363 -578
Total Operating Income		 -26 -68 -65 -159 47 -354 374 -673 -223 -467 -665
Total Gross Profit		 0.25 5.16 41 3.12 290 0.72 915 1.20 371 37 3.51
Total Revenue		 0.25 5.16 41 3.12 290 0.72 915 1.20 371 37 3.51
Operating Revenue		 0.25 5.16 41 3.12 290 0.72 915 1.20 371 37 3.51
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 26 73 106 162 243 355 541 674 594 504 668
Selling, General & Admin Expense		 13 31 36 48 63 86 100 102 76 73 74
Research & Development Expense		 13 42 70 114 179 221 341 462 387 310 381
Other Operating Expenses / (Income)		 - - - - - 48 101 110 130 121 213
Total Other Income / (Expense), net		 -0.09 45 -1.96 -5.49 21 6.38 6.00 23 72 104 87
Other Income / (Expense), net		 0.02 79 -0.20 -1.21 26 6.38 6.00 23 72 104 87
Income Tax Expense		 0.01 0.48 1.75 0.55 0.45 0.81 1.87 -0.33 2.89 3.59 3.63
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 0.01 0.02 -0.04 0.02 -0.02 -0.04 4.98 0.08 -0.07 0.07 -2.98
Basic Earnings per Share		 ($5.06) ($1.89) ($1.71) ($3.44) $1.23 ($5.29) $4.97 ($8.36) ($1.94) ($4.34) ($6.47)
Weighted Average Basic Shares Outstanding		 5.04M 12.26M 40.06M 47.96M 54.39M 65.95M 75.95M 77.75M 79.22M 84.36M 89.93M
Diluted Earnings per Share		 ($5.06) ($1.89) ($1.71) ($3.44) $1.17 ($5.29) $4.70 ($8.36) ($1.94) ($4.34) ($6.47)
Weighted Average Diluted Shares Outstanding		 5.04M 12.26M 40.06M 47.96M 56.93M 65.95M 80.39M 77.75M 79.22M 84.36M 89.93M
Weighted Average Basic & Diluted Shares Outstanding		 5.04M 12.26M 40.06M 47.96M 60.85M 75.43M 77.07M 78.65M 80.28M 85.77M 95.99M

Quarterly Income Statements for CRISPR Therapeutics

This table shows CRISPR Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 89 -117 -126 -86 -34 -134 -208 -106 -128 -123 -94
Consolidated Net Income / (Loss)		 89 -117 -126 -86 -37 -136 -209 -106 -131 -123 -91
Net Income / (Loss) Continuing Operations		 89 -117 -126 -86 -37 -136 -209 -106 -131 -123 -91
Total Pre-Tax Income 		90 -116 -125 -85 -37 -135 -207 -106 -130 -122 -90
Total Operating Income		 70 -141 -151 -110 -65 -148 -229 -132 -155 -130 -117
Total Gross Profit		 201 0.50 0.52 0.60 36 0.87 0.89 0.89 0.86 1.46 10
Total Revenue		 201 0.50 0.52 0.60 36 0.87 0.89 0.89 0.86 1.46 10
Operating Revenue		 201 0.50 0.52 0.60 36 0.87 0.89 0.89 0.86 1.46 10
Total Cost of Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Operating Expenses		 132 141 152 111 100 149 230 133 156 132 127
Selling, General & Admin Expense		 16 18 19 17 18 19 19 17 18 17 18
Research & Development Expense		 95 76 80 82 82 72 166 59 84 69 70
Other Operating Expenses / (Income)		 20 47 52 11 - 58 45 57 54 46 40
Total Other Income / (Expense), net		 20 25 26 25 28 14 22 26 25 8.16 27
Other Income / (Expense), net		 20 25 26 25 28 14 22 26 25 8.16 27
Income Tax Expense		 0.23 0.72 1.29 0.88 0.70 1.11 1.29 0.62 0.61 0.84 0.96
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 -0.06 0.01 -0.00 -0.08 -3.31 -2.30 -0.08 0.03 -3.06 0.03 2.69
Basic Earnings per Share		 $1.12 ($1.43) ($1.49) ($1.01) ($0.41) ($1.58) ($2.40) ($1.17) ($1.32) ($1.28) ($0.94)
Weighted Average Basic Shares Outstanding		 79.22M 81.79M 84.92M 85.23M 84.36M 85.94M 87.07M 91.31M 89.93M 96.05M 96.51M
Diluted Earnings per Share		 $1.12 ($1.43) ($1.49) ($1.01) ($0.41) ($1.58) ($2.40) ($1.17) ($1.32) ($1.28) ($0.94)
Weighted Average Diluted Shares Outstanding		 79.22M 81.79M 84.92M 85.23M 84.36M 85.94M 87.07M 91.31M 89.93M 96.05M 96.51M
Weighted Average Basic & Diluted Shares Outstanding		 80.28M 84.92M 85.17M 85.35M 85.77M 86.36M 90.95M 95.30M 95.99M 96.45M 96.69M

Annual Cash Flow Statements for CRISPR Therapeutics

This table details how cash moves in and out of CRISPR Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 155 162 -76 217 489 237 -246 -716 177 -91 49
Net Cash From Operating Activities		 59 -53 -70 -96 57 -238 539 -496 -260 -143 -345
Net Cash From Continuing Operating Activities		 59 -53 -70 -96 57 -238 539 -496 -263 -143 -345
Net Income / (Loss) Continuing Operations		 -26 -23 -68 -165 67 -349 378 -650 -154 -366 -582
Consolidated Net Income / (Loss)		 -26 -23 -68 -165 67 -349 378 -650 -154 -366 -582
Depreciation Expense		 0.13 0.93 3.02 3.52 4.73 9.18 18 24 20 19 19
Non-Cash Adjustments To Reconcile Net Income		 3.11 -35 21 55 34 68 116 110 64 48 145
Changes in Operating Assets and Liabilities, net		 82 4.23 -25 11 -48 33 27 20 -194 156 72
Net Cash From Investing Activities		 -1.15 32 -8.31 -2.77 1.33 -541 -1,035 -259 375 -280 -32
Net Cash From Continuing Investing Activities		 -1.15 32 -8.31 -2.77 1.33 -541 -1,035 -259 375 -280 -32
Purchase of Property, Plant & Equipment		 -1.15 -3.02 -7.81 -2.77 -6.68 -18 -82 -37 -9.47 -1.90 -0.91
Acquisitions		 - -0.10 - - 8.01 - 0.00 0.00 -2.50 0.00 -25
Purchase of Investments		 - - -0.50 0.00 0.00 -594 -1,509 -1,418 -1,066 -1,486 -1,018
Sale and/or Maturity of Investments		 - - - 0.00 0.00 71 556 1,196 1,453 1,208 1,012
Net Cash From Financing Activities		 97 183 2.61 316 431 1,016 251 39 63 332 426
Net Cash From Continuing Financing Activities		 97 183 2.61 316 431 1,016 251 39 63 332 426
Issuance of Common Equity		 - 89 - 316 431 1,016 251 39 63 332 426
Effect of Exchange Rate Changes		 0.01 - - - 0.02 0.04 -0.01 -0.08 0.07 -0.02 0.10

Quarterly Cash Flow Statements for CRISPR Therapeutics

This table details how cash moves in and out of CRISPR Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 -139 318 -223 -259 73 -63 -42 93 61 72 -132
Net Cash From Operating Activities		 -96 110 -96 -107 -50 -54 -114 -85 -93 -109 -83
Net Cash From Continuing Operating Activities		 -96 110 -96 -107 -50 -54 -114 -85 -93 -109 -83
Net Income / (Loss) Continuing Operations		 89 -117 -126 -86 -37 -136 -209 -106 -131 -123 -91
Consolidated Net Income / (Loss)		 89 -117 -126 -86 -37 -136 -209 -106 -131 -123 -91
Depreciation Expense		 4.90 4.83 4.85 4.74 4.84 4.74 4.65 4.43 5.66 4.32 4.28
Non-Cash Adjustments To Reconcile Net Income		 14 11 15 15 6.79 22 107 6.47 9.76 25 6.23
Changes in Operating Assets and Liabilities, net		 -204 210 10 -40 -24 55 -17 11 23 -15 -3.70
Net Cash From Investing Activities		 -81 -98 -127 -162 106 -20 70 -119 37 -411 -56
Net Cash From Continuing Investing Activities		 -81 -98 -127 -162 106 -20 70 -119 37 -411 -56
Purchase of Property, Plant & Equipment		 -0.74 -0.72 -0.71 -0.22 -0.25 -0.21 -0.12 -0.07 -0.52 -0.50 -0.65
Purchase of Investments		 -368 -334 -476 -409 -267 -206 -215 -334 -263 -751 -215
Sale and/or Maturity of Investments		 287 237 350 248 373 186 310 215 301 340 162
Net Cash From Financing Activities		 39 306 -0.47 9.64 17 11 2.26 297 116 592 7.18
Net Cash From Continuing Financing Activities		 39 306 -0.47 9.64 17 11 2.26 297 116 592 7.18
Repayment of Debt		 - - - - - 0.00 - - - -14 -1.12
Issuance of Common Equity		 39 306 -0.47 9.64 17 11 2.26 297 116 5.44 8.30
Effect of Exchange Rate Changes		 0.06 -0.01 0.00 0.08 -0.09 0.04 0.08 -0.03 0.00 -0.03 0.01

Annual Balance Sheets for CRISPR Therapeutics

This table presents CRISPR Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 159 345 271 489 1,067 1,828 2,752 2,243 2,230 2,242 2,265
Total Current Assets		 157 320 248 466 988 1,717 2,418 1,853 1,908 1,937 1,986
Cash & Equivalents		 156 316 240 457 944 1,169 923 212 389 298 348
Short-Term Investments		 - - - - 0.00 522 1,456 1,603 1,304 1,606 1,628
Prepaid Expenses		 0.54 1.51 6.00 9.66 44 26 38 38 14 8.31 9.84
Plant, Property, & Equipment, net		 1.33 21 19 19 31 42 138 164 152 134 116
Total Noncurrent Assets		 1.26 3.75 4.10 4.12 48 69 197 226 170 171 164
Other Noncurrent Operating Assets		 0.10 0.20 0.61 3.83 48 69 197 173 168 171 164
Total Liabilities & Shareholders' Equity		 159 345 271 489 1,067 1,828 2,752 2,243 2,230 2,242 2,265
Total Liabilities		 124 112 84 97 127 164 352 368 347 310 343
Total Current Liabilities		 10 22 15 28 57 94 120 121 109 88 149
Accounts Payable		 1.58 4.57 1.64 5.07 5.94 9.09 15 27 38 15 11
Accrued Expenses		 8.43 16 11 21 30 54 91 78 45 41 89
Current Deferred Revenue		 0.00 1.03 1.03 1.30 0.96 2.34 1.01 0.00 4.11 3.85 16
Current Deferred & Payable Income Tax Liabilities		 0.08 0.02 0.35 0.40 0.58 10 0.72 0.14 0.44 0.45 1.11
Other Current Liabilities		 0.06 0.06 0.14 0.12 19 19 12 16 21 28 32
Total Noncurrent Liabilities		 114 90 69 69 70 69 233 246 238 222 194
Long-Term Debt		 38 - - - - - - - - - 0.00
Other Noncurrent Operating Liabilities		 0.28 0.19 0.31 0.24 58 58 220 234 224 210 194
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -29 233 188 392 939 1,664 2,399 1,875 1,883 1,932 1,922
Total Preferred & Common Equity		 -29 233 188 392 939 1,664 2,399 1,875 1,883 1,932 1,922
Total Common Equity		 -29 233 188 392 939 1,664 2,399 1,875 1,883 1,932 1,922
Common Stock		 4.82 290 313 684 1,164 2,238 2,601 2,737 2,881 3,296 3,865
Retained Earnings		 -34 -57 -125 -292 -225 -574 -196 -846 -1,000 -1,366 -1,948
Treasury Stock		 0.00 0.00 0.00 -0.06 -0.06 -0.06 -0.06 -0.06 -0.06 -0.06 -0.06
Accumulated Other Comprehensive Income / (Loss)		 -0.01 -0.03 0.01 -0.01 0.01 -0.08 -5.07 -16 1.91 1.84 4.82

Quarterly Balance Sheets for CRISPR Therapeutics

This table presents CRISPR Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 2,244 2,197 2,087 2,439 2,340 2,256 2,166 2,030 2,245 2,726 2,651
Total Current Assets		 1,908 1,860 1,761 2,120 2,010 1,944 1,868 1,734 1,929 2,448 2,372
Cash & Equivalents		 344 445 528 707 484 226 235 194 286 423 291
Short-Term Investments		 1,539 1,323 1,212 1,401 1,517 1,710 1,620 1,528 1,629 2,018 2,073
Prepaid Expenses		 25 21 21 11 8.79 8.25 12 12 13 6.58 7.42
Plant, Property, & Equipment, net		 162 159 156 147 143 139 129 125 121 112 108
Total Noncurrent Assets		 174 178 170 172 186 174 169 171 195 165 171
Other Noncurrent Operating Assets		 168 173 170 172 175 174 169 171 167 165 171
Total Liabilities & Shareholders' Equity		 2,244 2,197 2,087 2,439 2,340 2,256 2,166 2,030 2,245 2,726 2,651
Total Liabilities		 389 381 359 355 359 316 337 319 329 911 904
Total Current Liabilities		 147 133 111 119 128 90 119 104 119 136 133
Accounts Payable		 45 28 26 16 9.45 16 13 9.75 12 14 11
Accrued Expenses		 86 90 66 76 92 47 85 74 84 75 70
Current Deferred Revenue		 0.00 0.00 3.50 4.07 4.76 4.48 3.02 2.13 1.30 15 15
Current Deferred & Payable Income Tax Liabilities		 0.27 0.56 0.18 1.21 0.45 0.84 1.24 0.72 3.43 0.64 0.49
Other Current Liabilities		 16 15 15 21 21 22 18 18 18 32 36
Total Noncurrent Liabilities		 243 248 248 236 231 227 217 214 210 775 771
Long-Term Debt		 - - - - - - - - - 585 586
Other Noncurrent Operating Liabilities		 230 236 232 223 218 214 205 202 198 190 185
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 1,855 1,816 1,728 2,084 1,981 1,940 1,829 1,711 1,916 1,815 1,747
Total Preferred & Common Equity		 1,855 1,816 1,728 2,084 1,981 1,940 1,829 1,711 1,916 1,815 1,747
Total Common Equity		 1,855 1,816 1,728 2,084 1,981 1,940 1,829 1,711 1,916 1,815 1,747
Common Stock		 2,764 2,802 2,824 3,202 3,227 3,258 3,327 3,418 3,728 3,887 3,913
Retained Earnings		 -899 -977 -1,089 -1,116 -1,243 -1,329 -1,502 -1,710 -1,817 -2,070 -2,162
Treasury Stock		 -0.06 -0.06 -0.06 -0.06 -0.06 -0.06 -0.06 -0.06 -0.06 -0.06 -0.06
Accumulated Other Comprehensive Income / (Loss)		 -9.39 -8.91 -6.80 -1.55 -2.88 11 4.14 4.04 4.99 -1.94 -4.63

Annual Metrics And Ratios for CRISPR Therapeutics

This table displays calculated financial ratios and metrics derived from CRISPR Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 1,990.69% 693.90% -92.38% 9,169.85% -99.75% 127,154.94% -99.87% 30,885.48% -89.95% -90.59%
EBITDA Growth		 -274.89% 144.19% -646.75% -153.37% 149.48% -537.27% 217.30% -257.57% 79.10% -162.37% -62.63%
EBIT Growth		 -274.66% 140.38% -724.59% -146.98% 145.44% -578.28% 209.04% -271.40% 76.83% -140.62% -59.37%
NOPAT Growth		 -288.25% -164.80% 5.11% -145.86% 141.73% -634.38% 249.81% -226.78% 66.94% -109.66% -42.44%
Net Income Growth		 -87.04% 10.17% -194.62% -141.35% 140.52% -621.80% 208.25% -272.16% 76.37% -138.43% -58.80%
EPS Growth		 -356.85% 62.65% 9.52% -101.17% 134.01% -552.14% 188.85% -277.87% 76.79% -123.71% -49.08%
Operating Cash Flow Growth		 1,339.89% -188.95% -32.60% -37.30% 158.89% -520.57% 326.11% -191.98% 47.48% 45.17% -141.65%
Free Cash Flow Firm Growth		 0.00% -169.00% -69.66% -34.06% 86.57% -1,554.72% 243.70% -240.78% 26.65% 50.07% -128.33%
Invested Capital Growth		 0.00% -3.49% 35.82% -17.02% 93.26% -500.53% 177.90% -65.42% 2,561.61% -84.90% -291.18%
Revenue Q/Q Growth		 0.00% 0.00% 272.16% -91.16% 36.16% -99.07% 1.39% -91.50% 118.35% -81.60% -90.84%
EBITDA Q/Q Growth		 0.00% 0.00% -525.40% -43.15% 60,445.31% -67.53% -7.58% 3.55% 61.46% -58.14% -19.87%
EBIT Q/Q Growth		 0.00% 0.00% -418.14% -41.98% 1,870.63% -65.49% -8.73% 3.48% 58.17% -53.36% -19.27%
NOPAT Q/Q Growth		 0.00% 0.00% 28.90% -40.98% 800.32% -50.38% -8.80% 2.06% 47.47% -40.37% -15.70%
Net Income Q/Q Growth		 0.00% 0.00% -32.99% -40.71% 693.03% -65.12% -8.31% 4.51% 56.55% -52.86% -19.11%
EPS Q/Q Growth		 0.00% 0.00% -144.53% -37.60% 348.94% -72.88% -0.84% 1.88% 56.50% -54.45% -16.37%
Operating Cash Flow Q/Q Growth		 0.00% -259.65% 2.94% -16.36% 127.35% -55.01% -0.89% -5.83% 6.22% 24.38% -14.06%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -22.04% 67.38% -25.66% -6.88% -7.39% -10.60% 32.57% -3.52%
Invested Capital Q/Q Growth		 0.00% 0.00% 29.13% 11.88% 88.51% -15.03% -42.83% 136.68% 1,655.34% 604.06% -91.95%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -10,358.70% 218.96% -150.79% -5,013.89% 26.76% -47,131.02% 43.44% -52,281.14% -35.26% -920.31% -15,911.28%
Operating Margin		 -10,416.60% -1,319.33% -157.69% -5,087.80% 16.14% -49,295.55% 40.82% -56,190.40% -59.95% -1,250.38% -18,933.65%
EBIT Margin		 -10,410.12% 201.05% -158.17% -5,126.54% 25.13% -48,408.34% 41.48% -54,298.83% -40.60% -971.93% -16,466.24%
Profit (Net Income) Margin		 -10,456.68% -449.30% -166.74% -5,281.08% 23.09% -48,520.86% 41.28% -54,271.70% -41.38% -981.54% -16,569.77%
Tax Burden Percent		 100.03% 102.13% 102.63% 100.34% 99.33% 100.23% 99.51% 99.95% 101.92% 100.99% 100.63%
Interest Burden Percent		 100.42% -218.82% 102.72% 102.67% 92.49% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.67% 0.00% 0.49% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -3,444.29% -160.45% -303.26% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -3,435.86% -160.58% -301.05% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 3,413.87% 152.28% 284.06% 0.00%
Return on Equity (ROE)		 -72.97% -17.30% -32.50% -56.89% 10.04% -26.80% 18.59% -30.42% -8.17% -19.20% -30.18%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,599.81% -3,347.07% -345.97% -155.73% 0.00%
Operating Return on Assets (OROA)		 -16.13% 4.12% -21.04% -42.13% 9.36% -24.05% 16.57% -26.05% -6.74% -16.22% -25.65%
Return on Assets (ROA)		 -16.20% -9.20% -22.18% -43.40% 8.59% -24.10% 16.49% -26.03% -6.87% -16.38% -25.81%
Return on Common Equity (ROCE)		 59.98% -13.14% -32.50% -56.89% 10.04% -26.80% 18.59% -30.42% -8.17% -19.20% -30.18%
Return on Equity Simple (ROE_SIMPLE)		 88.77% -9.96% -36.39% -42.07% 7.12% -20.96% 15.74% -34.67% -8.16% -18.96% 0.00%
Net Operating Profit after Tax (NOPAT)		 -18 -48 -45 -111 46 -248 372 -471 -156 -327 -465
NOPAT Margin		 -7,291.62% -923.53% -110.38% -3,561.46% 16.03% -34,506.88% 40.62% -39,333.28% -41.97% -875.26% -13,253.55%
Net Nonoperating Expense Percent (NNEP)		 -13.21% 11.21% -8.23% -15.36% 2.92% -7.65% 0.29% -8.43% 0.12% -2.20% -6.00%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -25.12% -8.27% -16.90% -24.21%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 5,426.32% 601.39% 87.43% 1,545.90% 21.92% 11,925.87% 10.90% 8,552.92% 20.52% 195.58% 2,095.21%
R&D to Revenue		 5,090.28% 817.93% 170.26% 3,641.90% 61.94% 30,790.26% 37.22% 38,534.64% 104.34% 859.34% 10,856.38%
Operating Expenses to Revenue		 10,516.60% 1,419.33% 257.69% 5,187.80% 83.86% 49,395.55% 59.18% 56,290.40% 159.95% 1,350.38% 19,033.65%
Earnings before Interest and Taxes (EBIT)		 -26 10 -65 -160 73 -348 380 -651 -151 -363 -578
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -26 11 -62 -157 77 -339 397 -626 -131 -343 -558
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 3.46 5.13 3.78 3.58 6.50 2.42 1.70 2.64 1.74 2.60
Price to Tangible Book Value (P/TBV)		 0.00 3.47 5.14 3.78 3.58 6.50 2.42 1.70 2.64 1.74 2.60
Price to Revenue (P/Rev)		 0.00 156.18 23.49 474.62 11.61 15,045.33 6.34 2,656.64 13.40 90.03 1,423.80
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 50.28 0.00 15.56 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 1.99% 0.00% 6.43% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 168.22 186.92 17.51 51.52 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 95.08 17.64 328.44 8.35 12,694.38 3.74 1,097.00 8.83 39.01 860.89
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 43.43 0.00 0.00 31.21 0.00 8.60 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 47.29 0.00 0.00 33.23 0.00 9.01 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 52.09 0.00 9.20 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 42.67 0.00 6.35 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 10.52 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 1.08 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 1.08 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -3.34 -1.63 -1.33 -1.21 -1.05 -1.01 -1.00 -0.99 -0.95 -0.94 -1.01
Leverage Ratio		 4.50 1.88 1.47 1.31 1.17 1.11 1.13 1.17 1.19 1.17 1.17
Compound Leverage Factor		 4.52 -4.11 1.50 1.35 1.08 1.11 1.13 1.17 1.19 1.17 1.17
Debt to Total Capital		 51.99% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 51.99% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 87.47% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -39.46% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 -1.50 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 4.60 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 -1.50 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -2.13 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 6.53 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 -2.13 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 5.24 6.67 8.36 17.09 39.64 11.56 4.64 8.89 6.12 7.66
Noncontrolling Interest Sharing Ratio		 182.20% 24.04% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 15.44 14.56 17.12 16.81 17.29 18.21 20.17 15.30 17.54 22.07 13.32
Quick Ratio		 15.39 14.49 16.70 16.46 16.53 17.93 19.85 14.99 17.41 21.97 13.25
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 65 -45 -76 -102 -14 -226 325 -458 -336 -168 -383
Operating Cash Flow to CapEx		 5,149.74% -1,752.65% -897.02% -3,470.57% 847.95% -1,298.43% 659.66% -1,333.07% -2,749.47% -7,510.47% -37,747.70%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.02 0.13 0.01 0.37 0.00 0.40 0.00 0.17 0.02 0.00
Accounts Receivable Turnover		 0.73 2.95 14.18 2.30 3,097.22 5.92 4,075.56 0.00 0.00 0.33 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.19 0.46 2.06 0.17 11.62 0.02 10.18 0.01 2.35 0.26 0.03
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 500.95 123.55 25.74 158.55 0.12 61.68 0.09 0.00 0.00 1,100.46 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 500.95 123.55 25.74 158.55 0.12 61.68 0.09 0.00 0.00 1,100.46 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -83 -86 -55 -64 -4.35 -26 20 7.03 187 28 -54
Invested Capital Turnover		 -0.01 -0.06 -0.58 -0.05 -8.42 -0.05 -317.25 0.09 3.82 0.35 -0.27
Increase / (Decrease) in Invested Capital		 -83 -2.90 31 -9.37 60 -22 46 -13 180 -159 -82
Enterprise Value (EV)		 0.00 491 723 1,026 2,418 9,127 3,420 1,314 3,277 1,456 3,022
Market Capitalization		 0.00 807 963 1,483 3,362 10,818 5,799 3,183 4,972 3,360 4,998
Book Value per Share		 ($5.78) $5.85 $4.58 $7.56 $17.02 $23.56 $31.35 $23.95 $23.70 $22.64 $20.17
Tangible Book Value per Share		 ($5.87) $5.84 $4.57 $7.55 $17.01 $23.55 $31.35 $23.95 $23.70 $22.64 $20.17
Total Capital		 74 233 188 392 939 1,664 2,399 1,875 1,883 1,932 1,922
Total Debt		 38 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 38 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -118 -316 -240 -457 -944 -1,690 -2,379 -1,868 -1,696 -1,904 -1,976
Capital Expenditures (CapEx)		 1.15 3.02 7.81 2.77 6.68 18 82 37 9.47 1.90 0.91
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -9.28 -17 -5.88 -18 -13 -68 -81 -83 106 -54 -139
Debt-free Net Working Capital (DFNWC)		 147 298 234 439 930 1,622 2,298 1,732 1,799 1,849 1,837
Net Working Capital (NWC)		 147 298 234 439 930 1,622 2,298 1,732 1,799 1,849 1,837
Net Nonoperating Expense (NNE)		 7.82 -24 23 54 -20 101 -5.97 179 -2.17 40 116
Net Nonoperating Obligations (NNO)		 -118 -319 -243 -457 -944 -1,690 -2,379 -1,868 -1,696 -1,904 -1,976
Total Depreciation and Amortization (D&A)		 0.13 0.93 3.02 3.52 4.73 9.18 18 24 20 19 19
Debt-free, Cash-free Net Working Capital to Revenue		 -3,755.47% -335.59% -14.35% -576.18% -4.60% -9,453.69% -8.91% -6,961.52% 28.45% -145.99% -3,968.01%
Debt-free Net Working Capital to Revenue		 59,386.64% 5,774.40% 570.47% 14,041.26% 321.30% 225,641.31% 251.12% 144,567.53% 484.71% 4,956.18% 52,323.39%
Net Working Capital to Revenue		 59,386.64% 5,774.40% 570.47% 14,041.26% 321.30% 225,641.31% 251.12% 144,567.53% 484.71% 4,956.18% 52,323.39%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($5.06) ($1.89) ($1.71) ($3.44) $1.23 ($5.29) $4.97 ($8.36) ($1.94) ($4.34) ($6.47)
Adjusted Weighted Average Basic Shares Outstanding		 5.04M 39.81M 46.98M 52.28M 54.39M 65.95M 75.95M 77.75M 79.22M 84.36M 89.93M
Adjusted Diluted Earnings per Share		 ($5.06) ($1.89) ($1.71) ($3.44) $1.17 ($5.29) $4.70 ($8.36) ($1.94) ($4.34) ($6.47)
Adjusted Weighted Average Diluted Shares Outstanding		 5.04M 39.81M 46.98M 52.28M 56.93M 65.95M 80.39M 77.75M 79.22M 84.36M 89.93M
Adjusted Basic & Diluted Earnings per Share		 ($5.06) ($1.89) ($1.71) ($3.44) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 5.04M 12.26M 40.06M 47.96M 60.85M 75.43M 77.07M 78.65M 80.28M 85.77M 95.99M
Normalized Net Operating Profit after Tax (NOPAT)		 -18 -48 -45 -111 46 -248 372 -471 -156 -327 -465
Normalized NOPAT Margin		 -7,291.62% -923.53% -110.38% -3,561.46% 16.03% -34,506.88% 40.62% -39,333.28% -41.97% -875.26% -13,253.55%
Pre Tax Income Margin		 -10,453.85% -439.93% -162.47% -5,263.38% 23.24% -48,408.34% 41.48% -54,298.83% -40.60% -971.93% -16,466.24%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -1.43% -7.80% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for CRISPR Therapeutics

This table displays calculated financial ratios and metrics derived from CRISPR Therapeutics' official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 - - - - - - - - - 95,985,312.00 96,448,792.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - 95,985,312.00 96,448,792.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - -1.28 -0.97
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 3,353,333.33% -99.50% -99.26% 0.00% -82.26% 71.63% 72.53% 47.67% -97.58% 68.55% 1,041.37%
EBITDA Growth		 182.73% -137.79% -67.38% 24.80% -133.63% -17.22% -68.45% -26.22% -291.38% 9.51% 57.60%
EBIT Growth		 174.62% -123.92% -62.88% 23.87% -140.87% -16.42% -65.65% -24.40% -255.08% 9.49% 56.48%
NOPAT Growth		 175.37% -118.01% -58.85% 16.83% -165.15% -5.57% -51.61% -19.91% -139.61% 12.25% 48.86%
Net Income Growth		 180.80% -119.71% -62.60% 23.37% -141.76% -16.64% -64.98% -23.85% -250.07% 9.61% 56.29%
EPS Growth		 180.00% -113.43% -52.04% 28.37% -136.61% -10.49% -61.07% -15.84% -221.95% 18.99% 60.83%
Operating Cash Flow Growth		 15.23% 1,147.32% 28.27% -168.25% 47.92% -149.15% -19.14% 20.84% -84.99% -101.86% 26.68%
Free Cash Flow Firm Growth		 -40.53% -930.14% 66.55% 6.70% 202.68% 6.30% -488.60% 35.27% -122.93% 25.91% 66.76%
Invested Capital Growth		 2,561.61% 30.08% -174.11% 133.35% -84.90% -8.00% 68.29% -801.22% -291.18% -59.84% -212.53%
Revenue Q/Q Growth		 0.00% -99.75% 2.58% 16.44% 5,828.74% -97.58% 3.12% -0.34% -2.81% 68.75% 598.29%
EBITDA Q/Q Growth		 188.45% -217.52% -8.32% 33.21% 60.45% -309.68% -55.67% 49.96% -22.63% 5.28% 27.05%
EBIT Q/Q Growth		 180.17% -229.34% -7.99% 32.01% 56.96% -268.43% -53.65% 48.94% -22.85% 6.08% 26.13%
NOPAT Q/Q Growth		 174.88% -241.80% -7.59% 27.19% 41.35% -129.80% -54.51% 42.41% -17.19% 15.84% 9.96%
Net Income Q/Q Growth		 179.67% -230.49% -8.42% 32.01% 56.59% -264.49% -53.35% 48.96% -22.71% 5.88% 25.85%
EPS Q/Q Growth		 179.43% -227.68% -4.20% 32.21% 59.41% -285.37% -51.90% 51.25% -12.82% 3.03% 26.56%
Operating Cash Flow Q/Q Growth		 -141.05% 214.24% -187.09% -11.85% 53.20% -7.83% -111.10% 25.68% -9.36% -17.66% 23.32%
Free Cash Flow Firm Q/Q Growth		 -10.90% 1.71% 71.54% -200.71% 222.05% -189.70% -78.80% 66.93% 56.76% -189.80% 19.78%
Invested Capital Q/Q Growth		 1,655.34% -112.93% -31.82% 112.59% 604.06% -192.46% 61.29% -178.28% -91.95% 22.69% 24.32%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 46.96% -22,030.56% -23,264.22% -13,343.36% -89.01% -15,046.36% -22,713.90% -11,404.84% -14,390.97% -8,077.71% -843.87%
Operating Margin		 34.58% -27,894.25% -29,257.25% -18,294.02% -180.97% -17,158.84% -25,708.97% -14,854.78% -17,912.50% -8,933.33% -1,151.84%
EBIT Margin		 44.52% -22,989.48% -24,201.35% -14,130.56% -102.58% -15,593.87% -23,235.09% -11,903.49% -15,046.18% -8,373.94% -885.91%
Profit (Net Income) Margin		 44.41% -23,133.13% -24,450.29% -14,276.08% -104.54% -15,722.08% -23,379.93% -11,973.12% -15,117.25% -8,431.48% -895.33%
Tax Burden Percent		 99.74% 100.62% 101.03% 101.03% 101.91% 100.82% 100.62% 100.58% 100.47% 100.69% 101.06%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.26% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 131.89% 0.00% -743,692.69% 0.00% -43.89% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 130.77% 0.00% -743,691.61% 0.00% -44.33% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 -124.01% 0.00% 741,510.07% 0.00% 41.83% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 7.88% -11.03% -2,182.62% -13.07% -2.06% -19.71% -25.34% -25.33% -30.18% -31.21% -26.09%
Cash Return on Invested Capital (CROIC)		 -345.97% 0.00% 0.00% -6,197.88% -155.73% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 7.39% -2,667.51% -2,157.51% -1,319.88% -1.71% -255.15% -404.66% -202.75% -23.43% -14.05% -5.07%
Return on Assets (ROA)		 7.37% -2,684.17% -2,179.70% -1,333.47% -1.74% -257.25% -407.18% -203.94% -23.54% -14.14% -5.12%
Return on Common Equity (ROCE)		 7.88% -11.03% -2,182.62% -13.07% -2.06% -19.71% -25.34% -25.33% -30.18% -31.21% -26.09%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -10.42% -13.42% -12.35% 0.00% -21.08% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 69 -98 -106 -77 -45 -104 -161 -92 -108 -91 -82
NOPAT Margin		 34.49% -19,525.97% -20,480.08% -12,805.81% -126.68% -12,011.19% -17,996.28% -10,398.35% -12,538.75% -6,253.33% -806.29%
Net Nonoperating Expense Percent (NNEP)		 1.12% -0.91% -1.08% -0.48% 0.44% -1.62% -2.57% -0.72% -1.15% -1.71% -0.52%
Return On Investment Capital (ROIC_SIMPLE)		 3.69% - - - -2.34% -5.68% -9.38% -4.82% -5.64% -3.80% -3.52%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 8.19% 3,562.10% 3,768.09% 2,893.52% 50.78% 2,230.75% 2,120.63% 1,904.50% 2,129.51% 1,178.53% 172.41%
R&D to Revenue		 47.29% 15,113.49% 15,505.80% 13,647.84% 230.19% 8,379.65% 18,626.35% 6,625.65% 9,667.36% 4,703.29% 683.87%
Operating Expenses to Revenue		 65.42% 27,994.25% 29,357.25% 18,394.02% 280.97% 17,258.84% 25,808.97% 14,954.78% 18,012.50% 9,033.33% 1,251.84%
Earnings before Interest and Taxes (EBIT)		 90 -116 -125 -85 -37 -135 -207 -106 -130 -122 -90
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 94 -111 -120 -80 -32 -130 -203 -101 -124 -118 -86
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.64 2.60 2.32 2.06 1.74 1.60 2.46 3.08 2.60 2.52 3.01
Price to Tangible Book Value (P/TBV)		 2.64 2.60 2.32 2.06 1.74 1.60 2.46 3.08 2.60 2.52 3.01
Price to Revenue (P/Rev)		 13.40 19.93 22.68 19.73 90.03 77.48 110.40 153.75 1,423.80 1,112.85 392.80
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 17.51 0.00 0.00 514.72 51.52 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 8.83 12.17 12.73 10.18 39.01 28.23 65.16 103.04 860.89 660.42 260.02
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.32 0.34
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.32 0.34
Financial Leverage		 -0.95 -1.01 -1.00 -1.00 -0.94 -1.01 -1.01 -1.01 -1.01 -1.02 -1.01
Leverage Ratio		 1.19 1.19 1.19 1.18 1.17 1.18 1.18 1.17 1.17 1.34 1.35
Compound Leverage Factor		 1.19 1.19 1.19 1.18 1.17 1.18 1.18 1.17 1.17 1.34 1.35
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 24.39% 25.13%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 24.39% 25.13%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 75.61% 74.87%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.07 -1.37
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.40 4.14
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.07 -1.37
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.29 -1.57
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.10 4.75
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.29 -1.57
Altman Z-Score		 9.24 9.45 7.80 7.71 6.60 5.01 7.38 10.44 8.31 2.81 3.26
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 17.54 17.81 15.73 21.64 22.07 15.64 16.61 16.22 13.32 17.96 17.85
Quick Ratio		 17.41 17.72 15.66 21.55 21.97 15.53 16.49 16.10 13.25 17.92 17.79
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -111 -109 -31 -93 114 -102 -182 -60 -26 -76 -61
Operating Cash Flow to CapEx		 -13,018.02% 15,222.19% -13,519.38% -48,818.72% -19,697.24% -26,187.86% -97,333.33% -114,370.27% -17,901.93% -21,606.55% -12,885.49%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.17 0.12 0.09 0.09 0.02 0.02 0.02 0.02 0.00 0.00 0.01
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.33 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 2.35 1.76 1.34 1.38 0.26 0.27 0.28 0.30 0.03 0.03 0.12
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 1,100.46 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 1,100.46 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 187 -24 -32 4.01 28 -26 -10 -28 -54 -42 -32
Invested Capital Turnover		 3.82 -9.24 36.31 -50.59 0.35 -1.50 -1.81 -3.18 -0.27 -0.12 -0.64
Increase / (Decrease) in Invested Capital		 180 10 -75 16 -159 -1.94 22 -32 -82 -16 -21
Enterprise Value (EV)		 3,277 3,306 2,574 2,066 1,456 1,064 2,479 3,950 3,022 2,710 3,482
Market Capitalization		 4,972 5,414 4,586 4,001 3,360 2,919 4,201 5,894 4,998 4,566 5,260
Book Value per Share		 $23.70 $25.48 $23.33 $22.77 $22.64 $21.33 $19.81 $21.07 $20.17 $18.90 $18.11
Tangible Book Value per Share		 $23.70 $25.48 $23.33 $22.77 $22.64 $21.33 $19.81 $21.07 $20.17 $18.90 $18.11
Total Capital		 1,883 2,084 1,981 1,940 1,932 1,829 1,711 1,916 1,922 2,400 2,333
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 585 586
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 585 586
Net Debt		 -1,696 -2,108 -2,013 -1,936 -1,904 -1,855 -1,721 -1,944 -1,976 -1,856 -1,778
Capital Expenditures (CapEx)		 0.74 0.72 0.71 0.22 0.25 0.21 0.12 0.07 0.52 0.50 0.65
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 106 -107 -119 -82 -54 -107 -92 -106 -139 -130 -125
Debt-free Net Working Capital (DFNWC)		 1,799 2,001 1,883 1,854 1,849 1,748 1,629 1,810 1,837 2,312 2,239
Net Working Capital (NWC)		 1,799 2,001 1,883 1,854 1,849 1,748 1,629 1,810 1,837 2,312 2,239
Net Nonoperating Expense (NNE)		 -20 18 21 8.85 -7.90 32 48 14 22 32 9.07
Net Nonoperating Obligations (NNO)		 -1,696 -2,108 -2,013 -1,936 -1,904 -1,855 -1,721 -1,944 -1,976 -1,856 -1,778
Total Depreciation and Amortization (D&A)		 4.90 4.83 4.85 4.74 4.84 4.74 4.65 4.43 5.66 4.32 4.28
Debt-free, Cash-free Net Working Capital to Revenue		 28.45% -39.56% -58.86% -40.21% -145.99% -284.33% -241.61% -275.39% -3,968.01% -3,161.32% -936.96%
Debt-free Net Working Capital to Revenue		 484.71% 736.31% 930.93% 914.11% 4,956.18% 4,640.12% 4,282.01% 4,721.64% 52,323.39% 56,350.87% 16,718.00%
Net Working Capital to Revenue		 484.71% 736.31% 930.93% 914.11% 4,956.18% 4,640.12% 4,282.01% 4,721.64% 52,323.39% 56,350.87% 16,718.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $1.12 ($1.43) ($1.49) ($1.01) ($0.41) ($1.58) ($2.40) ($1.17) ($1.32) ($1.28) ($0.94)
Adjusted Weighted Average Basic Shares Outstanding		 79.22M 81.79M 84.92M 85.23M 84.36M 85.94M 87.07M 91.31M 89.93M 96.05M 96.51M
Adjusted Diluted Earnings per Share		 $1.12 ($1.43) ($1.49) ($1.01) ($0.41) ($1.58) ($2.40) ($1.17) ($1.32) ($1.28) ($0.94)
Adjusted Weighted Average Diluted Shares Outstanding		 79.22M 81.79M 84.92M 85.23M 84.36M 85.94M 87.07M 91.31M 89.93M 96.05M 96.51M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 80.28M 84.92M 85.17M 85.35M 85.77M 86.36M 90.95M 95.30M 95.99M 96.45M 96.69M
Normalized Net Operating Profit after Tax (NOPAT)		 69 -98 -106 -77 -45 -104 -161 -92 -108 -91 -82
Normalized NOPAT Margin		 34.49% -19,525.97% -20,480.08% -12,805.81% -126.68% -12,011.19% -17,996.28% -10,398.35% -12,538.75% -6,253.33% -806.29%
Pre Tax Income Margin		 44.52% -22,989.48% -24,201.35% -14,130.56% -102.58% -15,593.87% -23,235.09% -11,903.49% -15,046.18% -8,373.94% -885.91%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

CRISPR Therapeutics (NASDAQ: CRSP) continues to look like a cash-rich development-stage biotech, but its financial statements still show a business that is generating minimal revenue and burning significant cash to fund research and development.

  • Strong liquidity position: As of Q1 2026, CRSP held about $2.44 billion in current assets, including $423.3 million in cash and $2.02 billion in short-term investments.
  • Debt financing added flexibility: The company issued $600 million of debt in Q1 2026, which helped lift cash and support operations.
  • Cash balance improved sequentially: Cash and equivalents rose from $286.5 million at Q3 2025 to $423.3 million at Q1 2026.
  • Balance sheet remains equity-backed: Total equity was $1.81 billion in Q1 2026, far above total liabilities of $911.3 million.
  • Operating revenue improved year over year: Q1 2026 revenue was $1.46 million, up from $865,000 in Q1 2025.
  • Revenue remains very small: Quarterly sales are still in the low single-digit millions, which is not enough to offset operating costs.
  • Other income is helping results: Investment income and other non-operating gains continue to partially cushion losses.
  • Investments remain a major part of assets: The company’s liquidity is concentrated in cash and marketable securities rather than operating assets.
  • Large quarterly losses continue: Q1 2026 net loss was $122.9 million, only a slight improvement from $130.6 million in Q4 2025.
  • Cash burn remains substantial: Operating cash flow was negative $108.9 million in Q1 2026, after negative $92.6 million in Q4 2025.
  • R&D spending remains high: Research and development expense was $68.6 million in Q1 2026, reflecting continued heavy investment in pipeline development.
  • Profitability still distant: The company has posted consistent net losses across the last four years, including very large quarterly losses in 2024 and 2025.
  • Share count has risen over time: Basic shares outstanding climbed from roughly 81.8 million in Q1 2024 to 96.1 million in Q1 2026, which can dilute future earnings per share.

Bottom line: CRISPR Therapeutics has an enviable cash cushion and enough liquidity to keep funding operations, but the financial statements still reflect a company that is deeply unprofitable and reliant on outside capital, investment income, and cash reserves. For investors, the key question is whether its pipeline can eventually scale revenue fast enough to justify the ongoing burn.

08/13/26 02:01 PM ETAI Generated. May Contain Errors.

CRISPR Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, CRISPR Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

CRISPR Therapeutics' net income appears to be on an upward trend, with a most recent value of -$581.60 million in 2025, rising from -$25.83 million in 2015. The previous period was -$366.25 million in 2024. Check out CRISPR Therapeutics' forecast to explore projected trends and price targets.

CRISPR Therapeutics' total operating income in 2025 was -$664.57 million, based on the following breakdown:
  • Total Gross Profit: $3.51 million
  • Total Operating Expenses: $668.08 million

Over the last 10 years, CRISPR Therapeutics' total revenue changed from $247 thousand in 2015 to $3.51 million in 2025, a change of 1,321.1%.

CRISPR Therapeutics' total liabilities were at $343.43 million at the end of 2025, a 10.8% increase from 2024, and a 176.9% increase since 2015.

In the past 10 years, CRISPR Therapeutics' cash and equivalents has ranged from $155.96 million in 2015 to $1.17 billion in 2020, and is currently $347.56 million as of their latest financial filing in 2025.

Over the last 10 years, CRISPR Therapeutics' book value per share changed from -5.78 in 2015 to 20.17 in 2025, a change of -449.1%.


Related Companies

Financial statements for NASDAQ:CRSP last updated on 8/3/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel